DrugBank

AUGUST 9, 2024

This high attrition rate directly results from the scientific and regulatory hurdles that drug candidates must overcome. The Investment Landscape Despite these challenges, the potential rewards for successful drug development are substantial. The market for cardiovascular drugs, valued at 155.6 billion by 2030.

Pharmaceuticals 77

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 77

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Vial

MAY 20, 2024

Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. The two broadest categories of drug development can be separated into the preclinical and clinical research stages. over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

NIH Director's Blog: Drug Development

MAY 15, 2018

Fortunately, the drug available to me then was effective, but I was pretty sick for a few days. Since that time, malarial drug resistance has become steadily more widespread. In fact, the treatment that cured me would be of little use today. References: [1] Overview of malaria treatment. World Health Organization.

Drug Development 52

Drug Development Drugs Disease Treatment 52

DrugBank

MARCH 7, 2024

As we step into 2024, the momentum is expected to continue, with analysts projecting the weight loss drug market to reach remarkable heights, potentially hitting $100 billion by the end of the decade. adults using obesity medications by 2030, further underlining the growing significance of this sector.

Pharmaceutical Companies 81

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 81

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drug development. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.

Pharmaceutical Companies 71

Pharmaceutical Companies Government Pharmaceuticals DNA 71

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030. Additionally, the ophthalmic drugs market, valued at USD 33.81 Additionally, the ophthalmic drugs market, valued at USD 33.81

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52